Frequently asked questions about Ozempic /Wegovy and pancreatitis Here are some of the most common concerns about pancreatitis that people bring up with their healthcare providers when considering GLP-1 treatment
The combination of reduced oral intake from appetite suppression and fluid losses from gastrointestinal symptoms creates a vulnerable period, especially during the first 812 weeks of therapy or following dose increases
Emerging research indicates potential benefits in reducing cancer risk, addressing substance use disorders, improving cardiovascular health, and even influencing reproductive health
The delayed gastric emptying, whilst therapeutically beneficial for glucose control and weight management, is also responsible for many of the gastrointestinal side effects associated with these medications
This could be because those with obesity had a more difficult time obtaining insurance benefits for these expensive medications
To see trusted alternatives, visit our guide to the top online GLP-1 providers